EP1794134A1 - 2-anilinopyrimidine substituee utilisee en tant que kinase a cycle cellulaire ou recepteur de la tyrosine kinase, leur production et leur utilisation en tant que medicament - Google Patents

2-anilinopyrimidine substituee utilisee en tant que kinase a cycle cellulaire ou recepteur de la tyrosine kinase, leur production et leur utilisation en tant que medicament

Info

Publication number
EP1794134A1
EP1794134A1 EP05793571A EP05793571A EP1794134A1 EP 1794134 A1 EP1794134 A1 EP 1794134A1 EP 05793571 A EP05793571 A EP 05793571A EP 05793571 A EP05793571 A EP 05793571A EP 1794134 A1 EP1794134 A1 EP 1794134A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
general formula
diseases
optionally
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05793571A
Other languages
German (de)
English (en)
Inventor
Arwed Cleve
Ulrich LÜCKING
Christopher West
Hans Briem
Gerhard Siemeister
Martin Krüger
Rolf Jautelat
Philip Lienau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447860&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1794134(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004049622A external-priority patent/DE102004049622A1/de
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of EP1794134A1 publication Critical patent/EP1794134A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Definitions

  • the present invention relates to substituted 2-anilino-pyrimidines as cell cycle kinase and / or receptor tyrosine kinase inhibitors, their preparation and use as medicaments for the treatment or prophylaxis of various diseases.
  • CDK cyclin-dependent kinases
  • VEGF Vascular Endothelial Growth Factors
  • VEGF ⁇ / EGF receptor system vascular Endothelial Growth Factors
  • Inhibitors of the VEGF ⁇ / EGF receptor system can inhibit the formation of a blood vessel system in the tumor, thereby separating the tumor from the oxygen and nutrient supply and thus inhibiting tumor growth.
  • Pyrimidines and analogues are already described as active ingredients such as, for example, the 2-anilino-pyrimidines as fungicides (DE 4029650) or substituted pyrimidine derivatives for the treatment of neurological or neurodegenerative diseases (WO 99/19305).
  • pyrimidine derivatives for example bis (anilino) - pyrimidine derivatives (WO 00/12486), 2-amino-4-substituted pyrimidines (WO 01/14375), purines (WO 99/02162), 5-cyano-pyrimidines (WO 02/04429), anilinopyrimidines (WO 00/12486) and 2-hydroxy-3-N, N-dimethylaminopropoxy-pyrimidines (WO 00/39101).
  • bis (anilino) - pyrimidine derivatives WO 00/12486
  • 2-amino-4-substituted pyrimidines WO 01/14375
  • purines WO 99/02162
  • 5-cyano-pyrimidines WO 02/04429
  • anilinopyrimidines WO 00/12486
  • 2-hydroxy-3-N, N-dimethylaminopropoxy-pyrimidines WO 00/39101
  • WO 02/096888 and WO 03/7076437 have disclosed pyrimidine derivatives which have inhibitory effects on CDKs.
  • Compounds containing a phenylsulfonamide group are known as inhibitors of human carbonic anhydrases (especially carbonahydrase-2) and are used as diuretics, among others for the treatment of glaucoma.
  • the object of the present invention is to provide compounds which have improved pharmaceutical properties, in particular a reduction of carbonic anhydrase-2 inhibition, as the already known CDK inhibitors.
  • a and D are each independently halogen, hydroxy,
  • Cyano for the group -OR 5 , for a C 3 -C 6 -cycloalkyl or for an optionally mono- or polysubstituted by identical or different substituents with halogen or hydroxy or with the group -OR 5 substituted C- ⁇ -C 4 alkyl in which the alkyl radical may optionally be branched,
  • X is -NH-, -N (C 1 -C 3 -alkyl) - or -O-, where the alkyl radical may optionally be branched,
  • R 1 is halogen or cyano
  • R 2 is optionally monosubstituted or polysubstituted, identically or differently, C 1 -C 3 -alkoxy-substituted hydroxy-C 1 -C -alkyl, where the alkyl radical may optionally be branched, or is an optionally substituted by hydroxyl or C 1 -C 3 -
  • R 3 and R 4 are each independently hydrogen or optionally mono- or polysubstituted by identical or different hydroxy or the group -OR 5 or -NR 6 R 7 substituted Ci-C 3 -alkyl, wherein the alkyl radical may optionally be branched , stand,
  • R 5 is optionally substituted by halogen-substituted Ci-C 4 alkyl, wherein the alkyl radical may optionally be branched, and R 6 and R 7 are each independently optionally one or more times, same or different with hydroxy or the group -OR 5 substituted C 1 -C 5 -alkyl,
  • the substances according to the invention simultaneously have a strongly reduced to no detectable carbonic anhydrase inhibition and simultaneously an improved inhibition of VEGF receptor tyrosine kinases against inhibition of aminopyrimidines which are unsubstituted or substituted in orthosteposition to the sulfonamide substituent on the phenyl ring of 2-anilino-pyrimidine.
  • the compounds of the invention have improved pharmaceutical properties, in particular by the reduction of carbonic anhydrase inhibition and by the improved VEGF receptor tyrosine kinase inhibition, whereby substances of the invention can inhibit the proliferation of tumor cells and / or tumor angiogenesis while reducing side effects by Carboanhydraserial.
  • Alkyl is in each case a straight-chain or branched alkyl radical, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl or decyl.
  • alkyl radical such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl or decyl.
  • Alkoxy is in each case a straight-chain or branched alkoxy radical, such as, for example, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec. Butyloxy, pentyloxy, isopentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, decyloxy, undecyloxy or dodecyloxy.
  • alkoxy radical such as, for example, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec. Butyloxy, pentyloxy, isopentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, decyloxy, undecyloxy or dodecyloxy.
  • Cycloalkyl is in each case to be understood as meaning cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • Halogen is in each case fluorine, chlorine, bromine or iodine.
  • Isomers are to be understood as meaning chemical compounds of the same empirical formula but of different chemical structure. In general, one distinguishes constitutional isomers and stereoisomers.
  • Constitutional isomers have the same molecular formula, but differ in how their atoms or atomic groups are linked. For this include functional isomers, positional isomers, tautomers or valence isomers.
  • Stereoisomers basically have the same structure (constitution) - and therefore also the same molecular formula - but differ by the spatial arrangement of the atoms.
  • Configuration isomers are stereoisomers that can only be converted into each other by bond breaking. These include enantiomers, diastereomers and E / Z (ice / trans) isomers.
  • Enantiomers are stereoisomers that behave in the same way as image and mirror image and have no plane of symmetry. All stereoisomers that are not enantiomers are called diastereomers. A special case is E / Z (ice / trans) isomers of double bonds. Conformational isomers are stereoisomers that can be converted into each other by the rotation of single bonds.
  • suitable salts are the physiologically tolerated salts of organic and inorganic bases, such as, for example, the readily soluble alkali and alkaline earth salts and N-methyl-glucamine, dimethylglucamine, ethyl-glucamine, lysine, 1,6-hexadiamine , Ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropanediol, Sovak base, 1-amino-2,3,4-butanetriol.
  • organic and inorganic bases such as, for example, the readily soluble alkali and alkaline earth salts and N-methyl-glucamine, dimethylglucamine, ethyl-glucamine, lysine, 1,6-hexadiamine , Ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, amino
  • physiologically acceptable salts of organic and inorganic acids are suitable, such as hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid and the like.
  • Cancer includes solid tumors or leukemia, in particular ataxia telangiectasia, basal cell carcinoma, bladder carcinoma, brain tumor, breast cancer, Cervix carcinoma, central nervous system tumors, colorectal carcinoma, endometrial carcinoma, gastric carcinoma, gastrointestinal carcinoma, head and neck tumors, acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairline leukemia, hepatic carcinoma, lung tumor, non-small cell
  • Lung Carcinoma Small Cell Lung Cancer
  • B-cell Lymphoma Hodgkin's Lymphoma
  • Non-Hodgkin 's Lymphoma T-Cell Lymphoma
  • Melanoma Mesothelioma, Myeloma, Myoma
  • Tumors of the Esophagus Oral Tumors, Ovarian Cancer, Pancreatic Tumors, Prostate Cancer, Renal Carcinoma Sarcoma, Kaposi 's sarcoma, leiomyosarcoma, skin cancer, squamous cell carcinoma, testicular cancer or thyroid cancer.
  • a particularly effective subgroup are those compounds of general formula I in which X is -NH- or -O-,
  • R 2 is optionally mono- or polysubstituted, identical or different
  • R 3 and R 4 are hydrogen and R 5 is C 1 -C 4 -alkyl, where the alkyl radical may optionally be branched, and
  • A, D and R 1 have the meanings given above, and their
  • a and D are each independently halogen, hydroxy, cyano or the group -OR 5 or optionally mono- or polysubstituted, identically or differently with halogen or hydroxy or with the group -OR 5 -substituted C 1 -C 4 -alkyl or C C 3 -C 6 -cycloalkyl, where the alkyl radical may optionally be branched, X is -NH-, -N (C 1 -C 3 -alkyl) - or -O-, where the alkyl radical may optionally be branched, R 1 is halogen or cyano,
  • R 2 is optionally mono- or polysubstituted, identical or different
  • R 3 and R 4 are each independently of one another hydrogen, and
  • R 5 is -CF 3 or C 1 -C 4 -alkyl, where the alkyl radical may optionally be branched, and their isomers, diastereomers, enantiomers and / or salts.
  • a and D are each independently of one another halogen, hydroxy, cyano, the group -OR 5 , a C 3 -C 6 -cycloalkyl or an optionally mono- or polysubstituted by identical or different halogen or hydroxyl-substituted C 1-10 C 4 alkyl, and
  • R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given above, and their isomers, diastereomers, enantiomers and / or salts.
  • a and D are each independently halogen, hydroxy, cyano or the group -OR 5 or optionally mono- or polysubstituted by identical or different halogen-substituted CrC 4 -alkyl or C 3 -C 6 -cycloalkyl, X is -NH - or -O- stand,
  • R 1 is halogen
  • R 2 represents hydroxyl optionally substituted by the group -OR 5
  • R 3 and R 4 are hydrogen and R 5 is Ci-C 4 alkyl, and their isomers, diastereomers, enantiomers and / or salts. Of particular importance are compounds of the general formula I in which
  • a and D are each independently of one another C 1 -C 4 -alkyl or halogen, X is -NH- or -O-,
  • R 1 is halogen or cyano
  • R 2 is a hydroxy-C 1 -C 5 -alkyl, where the alkyl radical may optionally be branched, or a C 3 -C 7 -cycloalkyl, R 3 and R 4 are hydrogen and R 5 is C 1 -C 4 -alkyl, and their isomers, diastereomers, enantiomers and / or salts.
  • X is -NH- or -O-
  • R 1 is halogen
  • R 2 is optionally substituted by the group -OR 5 hydroxy-d-Cs-alkyl
  • R 3 and R 4 are hydrogen, and their isomers, diastereomers, enantiomers and / or salts.
  • a and D are each independently of one another C 1 -C 4 -alkyl, X is -NH- or -O-,
  • R 1 is halogen
  • R 2 is a hydroxy-C 3 -C 5 -alkyl, wherein the alkyl radical may optionally be branched
  • R 3 or R 4 are hydrogen, and their isomers, diastereomers, enantiomers and / or salts and Compounds of general formula I 1 in the.
  • a and D are each independently of the other C 1 -C 4 alkyl, X is -NH-,
  • R 1 is cyano
  • R 2 is a C 3 -C 7 cycloalkyl
  • R 3 or R 4 are hydrogen, and their isomers, diastereomers, enantiomers and / or salts
  • a and D can each independently of one another represent halogen, hydroxy, cyano, the group -OR 5 , a C 3 -C 6 -cycloalkyl or an optionally mono- or polysubstituted, identical or different, with halogen or
  • Alkyl radical may optionally be branched, stand ,.
  • a and D each independently have the following meaning: halogen, hydroxy, cyano, the group -OR 5 , a C 3 -C 6 -cycloalkyl or an optionally mono- or polysubstituted, identical or different with halogen or
  • a and D are each independently C 1 -C 4 alkyl or halogen. Most preferably, A and D each independently represent CrC 4 -
  • Alkyl but especially both for methyl.
  • X can stand for:
  • alkyl radical may optionally be branched.
  • X has the meaning -NH- or -O-, most preferably -NH-.
  • R 1 can stand for: halogen or cyano.
  • R 1 is Br.
  • R 2 may represent: optionally mono- or polysubstituted by identical or different C 1 -C 3 -alkoxy-substituted hydroxy-C 1 -C 8 -alkyl, where the alkyl radical may optionally be branched, or represents an optionally hydroxy or C 1 -C 4 -alkyl radical; C 3 alkyl substituted C 3 -C 7 cycloalkyl,
  • R 2 has the meaning: optionally mono- or polysubstituted, identically or differently, C 1 -C 3 -alkoxy-substituted hydroxy-C 1 -C -alkyl, where the alkyl radical may optionally be branched, or for a C 3 -C 7 - Cycloalkyl. More preferably, R 2 has the meaning:
  • R 2 is a hydroxy-Ca-C ⁇ -alkyl, wherein the alkyl radical may optionally be branched or is a C 5 - or-C 6 -cycloalkyl. Most preferably R 2 has the following meaning:
  • R 2 is an optionally mono- or polysubstituted by identical or different C 1 -C 3 -alkoxy hydroxy C 1 -C 8 -alkyl which is optionally branched, is the bond between X and R 2 preferably via a non-terminal C atom of R 2 .
  • R 3 and R 4 may each independently of one another denote hydrogen or an optionally mono- or polysubstituted by identical or different hydroxy or the group -OR 5 or -NR 6 R 7 substituted C 1 - C 3 alkyl, wherein the Alkyl radical may optionally be branched.
  • R 3 and R 4 are hydrogen.
  • R 5 may represent: a C 1 -C 4 -alkyl optionally substituted by halogen, where the alkyl radical may optionally be branched.
  • R 5 is preferably C 1 -C 4 -alkyl, where the alkyl radical may optionally be branched.
  • R 6 and R 7 may each independently represent an optionally mono- or polysubstituted by identical or different hydroxy or the group -OR 5 substituted C- ⁇ -C 3 alkyl.
  • the compounds of the present invention substantially inhibit cyclic kinases, including their anticancer activity, such as solid tumors and leukemia, autoimmune diseases such as psoriasis, alopecia, and multiple sclerosis, chemotherapeutic-induced alopecia and mucositis, cardiovascular diseases such as strictures, Atherosclerosis and restenosis, infectious diseases such. As caused by unicellular parasites such as Trypanosoma, Toxoplasma or Plasmodium, or by fungi, nephrological diseases such.
  • autoimmune diseases such as psoriasis, alopecia, and multiple sclerosis
  • chemotherapeutic-induced alopecia and mucositis chemotherapeutic-induced alopecia and mucositis
  • cardiovascular diseases such as strictures, Atherosclerosis and restenosis
  • infectious diseases such as caused by unicellular parasites such as Trypanosoma, Toxoplasma or Plasmodium, or by fungi,
  • Glomerulonephritis chronic neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease, acute neurodegenerative diseases such as ischaemias of the brain and neurotrauma, viral infections such as. As cytomegalovirus infections, herpes, hepatitis B and C, and HIV-based diseases.
  • the eukaryotic cell division cycle ensures the duplication of the genome and its distribution to the daughter cells by coordinating and regulating one Sequence of events goes through.
  • the cell cycle is divided into four consecutive phases: the G1 phase represents the time before DNA replication in which the cell grows and is susceptible to external stimuli.
  • the S phase the cell replicates its DNA
  • the G2 phase it prepares for entry into mitosis.
  • mitosis M phase
  • the replicated DNA is separated and cell division is performed.
  • CDKs cyclin-dependent kinases
  • Cyc cyclin
  • CDK / Cyc pairs are active in the different phases of the cell cycle.
  • CDK / Cyc pairs important for the basic function of the cell cycle are, for example, CDK4 (6) / CycD, CDK2 / CycE, CDK2 / CycA-, CDK1 / CycA and CDK1 / CycB.
  • Some members of the CDK enzyme family have a regulatory function by affecting the activity of the aforementioned cell cycle CDKs, while other members of the CDK enzyme family have not yet been assigned a particular function.
  • CDK5 is characterized by the fact that it has an atypical, non-cyclic regulatory subunit (p35), and its activity in the brain is highest.
  • Rb retinoblastoma protein
  • Rb is a transcriptional co-repressor protein.
  • Rb binds and inactivates E2F-type transcription factors and forms transcriptional repressor complexes with histone deacetylases
  • HDAC HDAC-Rb-HSWI / SNF and Rb-HSWI / SNF. Ce // 101, 79- 89).
  • CDKs phosphorylation of Rb by CDKs release bound E2F transcription factors and lead to transcriptional activation of genes whose products are required for DNA synthesis and progression through S-phase.
  • Rb phosphorylation causes the dissolution of the Rb-HDAC complexes, thereby activating additional genes.
  • the phosphorylation of Rb by CDKs is equivalent to exceeding the "restriction point".
  • CDK2 / CycE and CDK2 / CycA complexes For the progression through the S-phase and its completion, the activity of the CDK2 / CycE and CDK2 / CycA complexes is necessary, e.g. For example, the activity of E2F-type transcription factors is turned off by CDK2 / CycA phosphorylation as soon as the cells enter S-phase.
  • CDK1 complexed with CycA or CycB controls the entry and passage of G2 and M ( Figure 1).
  • the cycle is strictly regulated and controlled.
  • the enzymes necessary for the progression through the cycle must be activated at the right time, and also switched off again as soon as the appropriate phase has passed.
  • Corresponding control points arrest the progression through the cell cycle if DNA damage is detected, or the DNA replication, or the structure of the spindle apparatus is not yet completed.
  • the activity of the CDKs is directly controlled by various mechanisms, such as cyclone synthesis and degradation, complexing of the CDKs with the corresponding cyclins, phosphorylation and dephosphorylation of regulatory threonine and tyrosine residues, and binding of natural inhibitory proteins. While the protein level of the CDKs in a proliferating cell is relatively constant, the amount of individual cyclins oscillates as the cycle proceeds. For example, expression of CycD during the early G1 phase is stimulated by growth factors, and expression of CycE is induced upon activation of E2F-type transcription factors when the restriction point is exceeded. The cyclins themselves are degraded by ubiquitin-mediated proteolysis.
  • CDK activating kinases phosphorylate Thr160 / 161 of CDK1
  • the family of Wee1 / Myt1 kinases inactivate CDK1 by phosphorylation of Thr14 and Tyr15.
  • These inactivating phosphorylations can be reversed by cdc25 phosphatases.
  • Very important is the regulation of the activity of the CDK / Cyc complexes by two families of natural CDK inhibitor proteins (CKIs), the protein products of the p21 gene family (p21, p27, p57) and the p16 gene family (p15, p16, p18, p19).
  • CKIs CDK inhibitor proteins
  • Members of the p21 family bind to cyclin complexes of CDKs 1, 2,4,6, but only inhibit complexes containing CDK1 or CDK2.
  • Members of the p16 family are specific inhibitors of the CDK4 and CDK6 complexes.
  • Control points allow the cell to track the orderly progression of each phase during the cell cycle.
  • the key control points are at the junction of G1 to S and G2 to M.
  • the G 1 checkpoint ensures that the cell does not begin DNA synthesis if it is not properly nourished, correctly interacts with other cells or the substrate, and their DNA is intact.
  • the G2 / M checkpoint ensures complete replication of the DNA and assembly of the mitotic spindle before the cell enters mitosis.
  • the G1 control point is activated by the gene product of the p53 tumor suppressor gene.
  • p53 is activated upon detection of changes in the metabolism or genomic integrity of the cell, and may either trigger a halt in cell cycle progression or apoptosis.
  • the transcriptional activation of the expression of the CDK inhibitor protein p21 by p53 plays a decisive role.
  • a second branch of the G1 control point involves activation of the ATM and Chk1 kinases following DNA damage by UV light or ionizing radiation, and finally phosphorylation and subsequent proteolytic degradation of cdc25A phosphatase (Milan N. et al., 2000) of human cdc25A in response to DNA damage, Science 288, 1425-1429). This results in a arrest of the cell cycle as the inhibitory phosphorylation of the CDKs is not removed.
  • both mechanisms are similarly involved in stopping the progression through the cell cycle.
  • Loss of cell cycle regulation and loss of control point function are characteristics of tumor cells.
  • the CDK-Rb signaling pathway is affected by mutations in over 90% of human tumor cells. These mutations eventually leading to inactivating phosphorylation of RB include overexpression of D and E cyclins by gene amplification or chromosomal translocations, inactivating mutations or deletions of p16-type CDK inhibitors, as well as increased (p27) or decreased (CycD ) Protein breakdown.
  • the second set of genes hit by mutations in tumor cells encodes components of the control points.
  • p53 which is essential for the G1 and G2 / M control points, is the most frequently mutated gene in human tumors (approximately 50%).
  • CDK1 / Cyc and CDK2 / Cyc complexes occupy a crucial position during cell cycle progression: (1) Both dominant-negative forms of CDK2 or CDK1, as well as transcriptional repression of CDK2 expression by anti-sense Oligonucleotides cause a stop of cell cycle progression. (2) The inactivation of the CycA gene in mice is lethal. (3) The disruption of the function of the CDK2 / CycA complex in cells by cell permeable peptides led to tumor cell-selective apoptosis (Chen YNP et al., 1999) Proc Natl. Acad., USA 96, 4325-4329).
  • CDK1 / Cyc complexes appear to functionally inactivate CDK2 / CycE complexes in mice that have inactivated the CDK2 gene or cyclin E genes and, unexpectedly, did not exhibit a lethal phenotype (Aleem E. et al., (2005) Cdc2-cyclin E complexes regulate the G1 / S phase transition, Nat. Cell Biol., 7: 831-836).
  • a pharmaceutical preparation in addition to the active ingredient for enteral or parenteral administration suitable pharmaceutical, organic or inorganic inert carrier materials, such as, for example, water, gelatin, gum arabic, lactose, starch , Magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • suitable pharmaceutical, organic or inorganic inert carrier materials such as, for example, water, gelatin, gum arabic, lactose, starch , Magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • the pharmaceutical preparations may be in solid form, for example as tablets, dragees, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions.
  • adjuvants such as preservatives, stabilizers, wetting agents or emulsifiers; Salts for changing the osmotic pressure or buffer.
  • Injection solutions or suspensions in particular aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are particularly suitable for parenteral use.
  • Surfactant auxiliaries such as salts of bile acids or animal or plant phospholipids, but also mixtures thereof, as well as liposomes or components thereof, can also be used as carrier systems.
  • tablets, dragees or capsules with talc and / or hydrocarbon carriers or binders such as lactose, corn or potato starch
  • talc and / or hydrocarbon carriers or binders such as lactose, corn or potato starch
  • the application can also take place in liquid form, for example as juice, which may be accompanied by a sweetener.
  • enteral, parenteral and oral applications are also the subject of the present invention.
  • the dosage of the active ingredients may vary depending on the route of administration, the age and weight of the patient, the nature and severity of the disease being treated, and similar factors.
  • the daily dose is 0.5-1000 mg, preferably 50-200 mg, which may be given as a single dose or divided into 2 or more daily doses.
  • compounds of the general formula I according to the invention also inhibit receptor tyrosine kinases and their ligands which specifically inhibit the function of endothelial cells.
  • Receptor tyrosine kinases and their ligands which specifically regulate the function of endothelial cells, are critically involved in both physiological and pathogenic angiogenesis.
  • VEGF / VEGF Receptor system In pathological situations associated with increased neovascularization, increased expression of angiogenic growth factors and their receptors has been found.
  • VEGF receptors are preferably significantly increased in the endothelial cells that are adjacent to or pass through the tumors.
  • VEGF Neutralizing Antibodies Kim et al., Nature 362, 841-844, 1993
  • retroviral expression of dominant negative VEGF receptor variants Millauer et al., Nature 367, 576-579, 1994
  • recombinant VEGF-neutralizing receptor variants Goldman et al., Proc Natl Acad., USA 95, 8795-8800, 1998)
  • low molecular weight inhibitors of VEGF receptor tyrosine kinase Fong et al., Cancer Res. 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al., Cancer Res. 60, 2178-2189, 2000
  • inhibition of angiogenesis is a potential mode of treatment for tumor diseases.
  • compounds of the invention can inhibit either cyclic dependent kinases such as CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, and VEGF receptor tyrosine kinases or cyclin-dependent kinases or VEGF receptor tyrosine kinases.
  • cyclic dependent kinases such as CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9
  • VEGF receptor tyrosine kinases or cyclin-dependent kinases or VEGF receptor tyrosine kinases.
  • Retinopathy neovascular glaucoma, autoimmune psoriasis, alopecia and multiple sclerosis, fibrotic disorders, cirrhosis, mesangial cell proliferative
  • Alzheimer's disease in acute neurodegenerative diseases ischemia of the brain and
  • Neurotrauma, and viral infections include cytomegalovirus infections, herpes, hepatitis B or C, and HIV disorders.
  • medicaments for the treatment of the diseases listed above which contain at least one compound according to the general formula (I), as well as medicaments with suitable formulating and carrier substances.
  • the compounds of the general formula I according to the invention are, inter alia, excellent inhibitors of the cyclin-dependent kinases, such as CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, or the VEGF receptor tyrosine kinases.
  • the isomer mixtures can be separated into the enantiomers or E / Z isomers by customary methods such as, for example, crystallization, chromatography or salt formation.
  • the preparation of the salts is carried out in a customary manner by adding a solution of the compound of formula I with the equivalent amount or an excess of a base or acid, optionally in solution, and separating the precipitate or working up the solution in a conventional manner.
  • A, D, R 3 and R 4 have the meanings given in the general formula (I), and their isomers, diastereomers, enantiomers and / or salts are likewise provided by the present invention.
  • Crystallization, chromatography or salt formation are separated into the enantiomers or E / Z isomers.
  • the preparation of the salts is carried out in a customary manner by adding a solution of the compound of formula I with the equivalent amount or an excess of a base or acid, optionally in solution, and separating the precipitate or working up the solution in a conventional manner.
  • Bakulovirus-infected insect cells were purchased from ProQinase GmbH, Freiburg.
  • the histone IHS used as kinase substrate is commercially available from Sigma.
  • CDK1 / CycB 200 ng / measuring point was incubated for 10 min at 22 ° C.
  • test substances (0 ⁇ M, as well as within the range 0.01-100 ⁇ M) in assay buffer [50 mM Tris / HCl pH8.0, 10 mM MgCl 2, 0.1 mM Na ortho-vanadate, 1.0 mM dithiothreitol, 0.5 ⁇ M adenosine trisphosphate (ATP), 10 ⁇ g / measurement point histone INS, 0.2 ⁇ Ci / measurement point 33P-gamma ATP, 0.05% NP40, 1.25% dimethylsulfoxide].
  • ATP adenosine trisphosphate
  • Bakulovirus-infected insect cells were purchased from ProQinase GmbH, Freiburg. Histone IHS, which was used as a kinase substrate, was purchased from Sigma. CDK2 / CycE (50 ng / measuring point) was incubated for 10 min at 22 ° C.
  • test substances (0 ⁇ M, as well as within the range 0.01-100 ⁇ M) in assay buffer [50 mM Tris / HCl pH8.0, 10 mM MgCl 2 , 0.1 mM Na ortho-vanadate, 1.0 mM dithiothreitol, 0.5 ⁇ M adenosine trisphosphate (ATP), 10 ⁇ g / measurement point histone IHS, 0.2 ⁇ Ci / measurement point 33 P-gamma ATP, 0, 05% NP40, 1.25% dimethylsulfoxide].
  • ATP adenosine trisphosphate
  • the reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 ⁇ l / measuring point).
  • VEGF receptor tyrosine kinase-2 was purified as a GST fusion protein from baculovirus-infected insect cells (Sf9).
  • Poly (Glu4Tyr) which was used as a kinase substrate, was purchased from Sigma.
  • VEGF receptor tyrosine kinase (90 ng / measuring point) was incubated for 10 min at 22 ° C. in the presence of various concentrations of test substances (0 ⁇ M and within the range 0.001-30 ⁇ M) in 30 ⁇ l assay buffer [40 mM Tris / HCl pH 5.5, 10 mM MgCl 2, 1 mM MnCl 2, 3 ⁇ M Na ortho-vanadate, 1.0 mM
  • Dithiothreitol 8 ⁇ M adenosine trisphosphate (ATP), 0.96 ⁇ g / assay poly (Glu4Tyr), 0.2 ⁇ Ci / assay 33P-gamma ATP, 1.4% dimethyl sulfoxide].
  • the reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 ⁇ l / measuring point). From each reaction, 15 ⁇ l was applied to P30 filter tape (Wallac) and unincorporated 33P-ATP was removed by washing the filter strips three times each for 10 minutes in 0.5% phosphoric acid. After drying the filter strip for 1 hour at 70 0 C., the filter strips with scintillator strips (MeltiLexTM A, Fa. Wallac) were covered and baked for 1 hour at 90 0 C. The amount of built-in 33P
  • Substrate phosphorylation was determined by scintillation measurement in a gamma radiation meter (Wallac). The IC50 values are determined from the inhibitor concentration necessary to inhibit phosphate incorporation to 50% of uninhibited post-zero insertion (EDTA-stopped reaction).
  • MCF7 hormone-independent human breast carcinoma cells purchased from ATCC HTB22, NCI-H460, human non-small cell lung carcinoma cells, ATCC HTB-177; DU 145, hormone-independent human prostate carcinoma cells, ATCC HTB-81; MaTu-MDR, hormone independent, multiple drug resistant human mammary carcinoma cells, EPO GmbH, Berlin
  • MCF7 hormone-independent human breast carcinoma cells purchased from ATCC HTB22, NCI-H460, human non-small cell lung carcinoma cells, ATCC HTB-177
  • DU 145 hormone-independent human prostate carcinoma cells, ATCC HTB-81
  • MaTu-MDR hormone independent, multiple drug resistant human mammary carcinoma cells, EPO GmbH, Berlin
  • the cells of one plate were stained with crystal violet (see below), while the medium of the other plates was replaced by fresh culture medium (200 ⁇ l) containing the test substances at various concentrations (0 ⁇ M and in the range 0.01 - 30 ⁇ M, the final concentration of the solvent dimethylsulfoxide was 0.5%) were added replaced.
  • the cells were incubated for 4 days in the presence of the test substances. Cell proliferation was determined by staining the cells with crystal violet.
  • the cells were added by adding 20 ⁇ l / measuring point of an 11% glutaraldehyde solution for 15 min
  • the principle of the assay is based on the hydrolysis of 4-nitrophenyl acetate by carbonic anhydrases (Pocker & Stone, Biochemistry, 1967, 6, 668.), followed by photometric determination of the resulting dye 4-nitrophenolate at 400 nm by means of a 96-channel spectrophotometer.
  • Quadipedes pipetted into the wells of a 96-well microtiter plate. Holes containing solvents without test compounds served as reference values (1st holes without carbonic anhydrase to correct the non-enzymatic hydrolysis of the substrate, and 2nd holes with carbonic anhydrase to determine the activity of the non-inhibited enzyme).

Abstract

L'invention concerne des dérivés de pyrimidine de formule (I), dans laquelle R<sup
EP05793571A 2004-09-29 2005-09-27 2-anilinopyrimidine substituee utilisee en tant que kinase a cycle cellulaire ou recepteur de la tyrosine kinase, leur production et leur utilisation en tant que medicament Withdrawn EP1794134A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61396404P 2004-09-29 2004-09-29
DE102004049622A DE102004049622A1 (de) 2004-10-06 2004-10-06 Subtituierte 2-Anilinopyrimidine als Zellzyklus-kinase oder Rezeptortyrosin-kinase Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
PCT/EP2005/010578 WO2006034872A1 (fr) 2004-09-29 2005-09-27 2-anilinopyrimidine substituee utilisee en tant que kinase a cycle cellulaire ou recepteur de la tyrosine kinase, leur production et leur utilisation en tant que medicament

Publications (1)

Publication Number Publication Date
EP1794134A1 true EP1794134A1 (fr) 2007-06-13

Family

ID=35447860

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05793571A Withdrawn EP1794134A1 (fr) 2004-09-29 2005-09-27 2-anilinopyrimidine substituee utilisee en tant que kinase a cycle cellulaire ou recepteur de la tyrosine kinase, leur production et leur utilisation en tant que medicament

Country Status (11)

Country Link
US (1) US20060111378A1 (fr)
EP (1) EP1794134A1 (fr)
JP (1) JP2008514571A (fr)
AR (1) AR052312A1 (fr)
GT (1) GT200500272A (fr)
PA (1) PA8647401A1 (fr)
PE (1) PE20061158A1 (fr)
SV (1) SV2006002245A (fr)
TW (1) TW200628452A (fr)
UY (1) UY29145A1 (fr)
WO (1) WO2006034872A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2005524672A (ja) * 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
WO2005016893A2 (fr) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. Methodes de traitement ou de prevention de maladies auto-immunes a l'aide de composes de 2,4-pyrimidinediamine
MX2007007272A (es) * 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
RU2416616C2 (ru) 2005-01-19 2011-04-20 Райджел Фармасьютикалз, Инк. Пролекарства соединений 2,4-пиримидиндиамина и их применения
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (fr) * 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions et procedes d'inhibition de la voie jak
AU2006274733B2 (en) * 2005-07-30 2010-09-16 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
UY29826A1 (es) * 2005-09-30 2007-04-30 Astrazeneca Ab Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
WO2007120980A2 (fr) 2006-02-17 2007-10-25 Rigel Pharmaceuticals, Inc. Composés de 2,4-pyrimidinediamine pour le traitement ou la prévention de maladies autoimmunes
CA2642229C (fr) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions et methodes destinees a l'inhibition de la voie jak
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
EP2179991A1 (fr) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Dérivés d'anilino-pyrimidine substitués par sulfoximine en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments
GB0821537D0 (en) * 2008-11-25 2008-12-31 Union Life Sciences Ltd Therapeutic target
KR101740076B1 (ko) * 2009-07-28 2017-06-08 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
CA2777071A1 (fr) * 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Derives d'halogenophenoxybenzamide substitues
EP2353591A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance
BR112016014412A2 (pt) 2013-12-20 2017-08-08 Signal Pharm Llc Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
EP3947368A4 (fr) * 2019-04-04 2023-01-04 Dana-Farber Cancer Institute, Inc. Agents de dégradation de cdk2/5 et utilisations associées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58183665A (ja) * 1982-04-19 1983-10-26 Sumitomo Chem Co Ltd スルホニルクロリドの製造方法
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
PL367130A1 (en) * 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US7288547B2 (en) * 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
JP2005526765A (ja) * 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006034872A1 *

Also Published As

Publication number Publication date
SV2006002245A (es) 2006-05-25
TW200628452A (en) 2006-08-16
WO2006034872A1 (fr) 2006-04-06
GT200500272A (es) 2006-06-06
US20060111378A1 (en) 2006-05-25
UY29145A1 (es) 2006-04-28
AR052312A1 (es) 2007-03-14
PE20061158A1 (es) 2006-11-12
JP2008514571A (ja) 2008-05-08
PA8647401A1 (es) 2006-07-03

Similar Documents

Publication Publication Date Title
EP1794134A1 (fr) 2-anilinopyrimidine substituee utilisee en tant que kinase a cycle cellulaire ou recepteur de la tyrosine kinase, leur production et leur utilisation en tant que medicament
EP1530574B1 (fr) Pyrimidines macrocycliques, leur production et leur utilisation comme medicament
EP1673352B1 (fr) Pyrimidines substituees sulfoximine en tant qu&#39;inhibiteurs de cdk et/ou vegf, leur production et leur utilisation comme medicaments
EP1392662B1 (fr) Pyrimidine inhibitrice de la cdk, sa production et son utilisation comme medicament
EP1387840B1 (fr) 3,5-diamino-1,2,4-triazoles en tant qu&#39;inhibiteurs de kinase
EP1705177A1 (fr) Pyrimidines substituées par une N-aryl-sulfoximine comme inhibiteurs de CDK et de VEGF, leur préparation et utilisation comme médicaments
EP1483260A1 (fr) 2-heteroaryle-pyrimidines inhibitrices de la kinase dependante des cyclines, leur production et leur utilisation comme medicaments
DE102005062742A1 (de) Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
WO2002044148A2 (fr) Derives d&#39;indirubine substitues par aryle, leur production et leur utilisation
WO2007079982A1 (fr) Dérivés de (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3 4-yl)-sulfoximide utilisés comme inhibiteurs sélectifs de la kinase aurora pour traiter le cancer
DE10148618A1 (de) Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10212098A1 (de) CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10127581A1 (de) CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE102004049622A1 (de) Subtituierte 2-Anilinopyrimidine als Zellzyklus-kinase oder Rezeptortyrosin-kinase Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE10212100A1 (de) CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10255984A1 (de) CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arnzeimittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070314

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KRUEGER, MARTIN

Inventor name: LIENAU, PHILIP

Inventor name: JAUTELAT, ROLF

Inventor name: CLEVE, ARWED

Inventor name: SIEMEISTER, GERHARD

Inventor name: LUECKING, ULRICH

Inventor name: WEST, CHRISTOPHER

Inventor name: BRIEM, HANS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080425

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080906